Aneyefor News

(Albany , US) , September 10 , 2026 – DelveInsight’s “Sciatica Treatment Market Insights, Epidemiology, and Market Forecast – 2032” report offers an in-depth understanding of sciatica, along with historical and forecasted epidemiology and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan, covering 2019 to 2032.

To know in detail about the Sciatica market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Sciatica Market Forecast

Some of the key facts of the Sciatica Market Report:

• The Sciatica Treatment Market across the 7MM is projected to expand at a notable CAGR through 2032, supported by an active late-stage pipeline of novel therapies.

• There is currently no FDA-approved drug specifically indicated for sciatica; available medications (NSAIDs, corticosteroids, muscle relaxants, anticonvulsants, opioids, antidepressants) are used largely off-label to manage pain and inflammation.

• SEMDEXA (SP-102), developed by Scilex Pharmaceuticals, is a non-opioid injectable corticosteroid gel formulation targeting lumbosacral radicular pain; it received FDA Fast Track designation in 2021 and is currently in pivotal Phase III trials in the US.

• STX-015, an alpha-2 adrenergic receptor agonist developed by Sollis Therapeutics, is being evaluated in Phase III trials for low back and leg pain associated with sciatica.

• SB0101, being developed by Sinfonia Biotherapeutics, is currently in Phase II development.

• The COVID-19 pandemic negatively impacted the Sciatica Treatment Market, as decreased hospital visits led to fewer diagnoses and delayed treatment initiation.

• The United States accounted for the largest share of the 7MM Sciatica market in 2022, attributed to high disease prevalence and higher treatment costs, a trend expected to continue with the potential early entry of new therapies.

• As per Clarke et al. (2016), roughly 54.5% of US adults report a musculoskeletal pain disorder (a category that includes sciatica, lower back pain, neck pain, and joint pain); based on National Health Interview Survey (2012) estimates, approximately 12 million people in the US are affected by sciatica.

• According to Koes et al. (2007), a herniated spinal disc pressing on a lumbar or sacral nerve root is responsible for roughly 90% of sciatica cases.

• Davis et al. (2022) found no clear gender predominance in sciatica, with a lifetime incidence estimated between 10% and 15%.

• Matsudaira et al. (2013), in a Japanese occupational cohort study, reported that 18.4% of eligible participants experienced a new sciatica episode.

• DelveInsight’s analysts engaged with more than 50 Key Opinion Leaders (KOLs) globally, conducting in-depth interviews with over 15 KOLs across the 7MM, including experts from Nantes Université (France) and the Department of Neurological Surgery at Duke University Medical Center (US).

• Key Sciatica Companies: Scilex Pharmaceuticals, Sollis Therapeutics, SpineThera, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon Life Science, Teijin America, and others.

• Key Sciatica Therapies: SEMDEXA (SP-102), STX-015, SB0101, and others.

Sciatica Overview

Sciatica refers to pain that radiates along the path of the sciatic nerve, extending from the lower back through the hips and buttocks and down each leg, typically affecting only one side of the body. It most commonly results from compression of the L4, L5, or S1 nerve roots, and less frequently from irritation of the S2/S3 nerve roots or the sciatic nerve itself. Common contributing factors include age-related spinal degeneration, obesity, occupations involving heavy lifting, prolonged sitting, and diabetes, with spinal disc herniation being the leading cause. Other potential causes include spondylolisthesis, musculoskeletal pain disorders, piriformis syndrome, pelvic tumors, and pregnancy. Sciatica can present as acute, chronic, alternating, or bilateral, and is typically diagnosed through physical examination combined with a review of symptom history and, where needed, imaging.

Get a Free sample for the Sciatica Market Report: https://www.delveinsight.com/report-store/sciatica-market

Sciatica Epidemiology

The epidemiology section provides insights into historical, current, and forecasted trends across the seven major markets (7MM) from 2019 to 2032, drawing on published studies and the perspectives of key opinion leaders to explain observed and projected trends, along with a detailed view of the diagnosed patient pool.

Sciatica Epidemiology Segmentation: The Sciatica market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Sciatica Diagnosed Prevalent Cases

• Sciatica Age-Specific Diagnosed Prevalent Cases

• Sciatica Comorbidities Associated with Diagnosed Prevalent Cases

Download the report to understand which factors are driving Sciatica epidemiology trends @ Sciatica Epidemiology Forecast

Sciatica Market

The dynamics of the Sciatica market are anticipated to shift over the coming years due to the expected entry of new therapies during the forecast period (2019–2032).

“The current Sciatica treatment landscape lacks disease-modifying therapies and standardized treatment guidelines; while symptomatic treatments are widely used, they offer only mild to moderate pain relief, underscoring a significant unmet need in the market.”

Sciatica Therapies and Key Companies

• SEMDEXA (SP-102) — Glucocorticoid receptor agonist, administered via epidural injection — Scilex Pharmaceuticals — Phase III

• STX-015 — Alpha-2 adrenergic receptor agonist — Sollis Therapeutics — Phase III

• SB0101 — Sinfonia Biotherapeutics — Phase II

To know more about Sciatica treatment, visit @ Sciatica Medications

Sciatica Market Drivers

• Rising Sciatica Incidence and Growing Geriatric Population

• Increasing Prevalence of Herniated Discs and Degenerative Disc Disease

• Advancements in Diagnostic Techniques

• Development of Novel, Non-Opioid Therapies

• Improved Healthcare Access

• Greater Disease Awareness Among Patients and Physicians

Sciatica Market Barriers

• Absence of FDA-Approved, Disease-Specific Therapies

• Lack of Standardized Treatment Guidelines

• Reliance on Off-Label Symptomatic Treatments

• High Costs and Limited Access to Advanced Therapies

• Inconsistent Care Due to Varying Physician Approaches

• Lingering Impact of Reduced Hospital Visits Post-COVID-19

Scope of the Sciatica Market Report

• Study Period: 2019–2032

• Forecast Period: 2023–2032

• Coverage: 7MM

• Key Sciatica Companies: Scilex Pharmaceuticals, Sollis Therapeutics, SpineThera, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon Life Science, Teijin America, and others

• Key Sciatica Therapies: SEMDEXA (SP-102), STX-015, SB0101, and others

• Sciatica Therapeutic Assessment: Current marketed therapies and emerging Sciatica therapies

• Sciatica Market Dynamics: Market drivers and market barriers

• Competitive Intelligence Analysis: SWOT analysis, Market entry strategies

• Sciatica Unmet Needs, KOL’s views, Analyst’s views, Sciatica Market Access and Reimbursement

Table of Content

1. Key Insights

2. Report Introduction

3. Sciatica Market Overview at a Glance

4. Key Events

5. Sciatica Epidemiology and Market Methodology

6. Executive Summary of Sciatica

7. Disease Background and Overview

8. Sciatica Epidemiology and Patient Population

9. Sciatica Marketed Therapies

10. Emerging Sciatica Therapies

11. Sciatica Patient Journey

12. Sciatica: 7MM Analysis

13. The United States: Sciatica Market Size

14. The EU4 and the UK Sciatica Market Size

15. Japan Sciatica Market Size

16. Sciatica Market Access and Reimbursement

17. Unmet Needs

18. SWOT Analysis

19. KOL Views

20. Appendix

21. DelveInsight’s Capabilities

22. Disclaimer

23. About DelveInsight’s

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, benefiting market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/sciatica-market